8-K: Propanc Biopharma Secures $50,000 in High-Cost Promissory Note Financing

Propanc Biopharma Inc. has entered into a material definitive agreement for a $60,000 principal promissory note, purchased for $50,000, to fund general working capital, signaling a high cost of capital.

Summary

• Propanc Biopharma Inc. (the "Company") issued a Promissory Note with a principal amount of $60,000 to Ionic Ventures, LLC, an accredited investor, for a purchase price of $50,000.
• The Note has an Original Issue Discount (OID) of $10,000, meaning the Company received $50,000 but is obligated to repay $60,000 plus interest.
• The maturity date for the Note is July 15, 2025, and it bears interest at an annual rate of ten percent (10%).
• If the Company repays the Note on or before July 7, 2025, it must pay 100% of the outstanding Principal Amount plus accrued interest.
• If the Company repays the Note after July 7, 2025, and on or before August 7, 2025, it must pay 120% of the outstanding Principal Amount (i.e., $72,000) plus accrued interest, referred to as the Maximum Repayment Amount.
• The net proceeds from this financing are intended for general working capital purposes.
• The Note is not a convertible instrument and has no contractual rights to convert into equity of the Borrower.
• A late fee of 10% per annum applies to any obligation not paid within ten calendar days of its due date.
• In the event of default, the outstanding principal, accrued interest, fees, and liquidated damages become immediately due and payable at the Maximum Repayment Amount, and the interest rate increases to eighteen percent (18%) per annum.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the high cost of capital, significant Original Issue Discount, and punitive repayment terms, which suggest financial pressure on the Company. While capital was secured, the terms are unfavorable.

Positives

• The Company successfully secured $50,000 in immediate capital to support general working capital purposes.

Negatives

• The Note was issued at a significant Original Issue Discount (OID) of $10,000, meaning the Company received only $50,000 for a $60,000 principal obligation.
• The effective cost of capital is very high due to the OID and the potential 120% repayment clause, which could result in a $22,000 premium ($72,000 repayment on a $50,000 investment) over a short period, in addition to 10% interest.
• The repayment terms are punitive, requiring a 120% repayment of the principal amount if not repaid within approximately 37 days of the effective issuance date.
• A high default interest rate of 18% per annum is imposed upon any Event of Default, further increasing the financial burden on the Company.

Risks

• Default in payment of principal, interest, or other charges not cured within two trading days.
• Failure to observe or perform any other material covenant or agreement not cured within five business days (after Lender notice) or ten business days (after Borrower awareness).
• Breach of any representations and warranties set forth in the Note or related transaction documents.
• Commencement of bankruptcy or insolvency proceedings against the Borrower that remain undismissed for 60 days, or adjudication of insolvency.
• Breach or default under any other indebtedness of the Borrower exceeding $50,000, or such indebtedness becoming due and payable prior to its scheduled date.
• Any monetary judgment, writ, or similar final process exceeding $50,000 entered against the Borrower or its assets that remains unvacated, unbonded, or unstayed for 30 calendar days.
• Levy, seizure, attachment, or uninsured loss/damage to any asset of the Borrower exceeding $50,000 that is not set aside, bonded, or discharged within 30 days.

Future Outlook

The Company intends to use the net proceeds from this financing for general working capital purposes, indicating a focus on immediate operational needs.

Management Comments

• James Nathanielsz, Chief Executive Officer and Chief Financial Officer, signed the report on behalf of Propanc Biopharma Inc.

Industry Context

This type of short-term, high-cost debt financing with a significant Original Issue Discount is often utilized by early-stage biopharma companies or those facing liquidity challenges, as they may have limited access to traditional bank loans or more favorable equity financing due to their high-risk profile, lack of consistent revenue, or specific market conditions. It suggests a need for immediate capital to bridge operational gaps or fund ongoing research and development without diluting existing shareholders through equity issuance at potentially low valuations.

Comparison to Industry Standards

• The terms of this promissory note, including the 10% OID, 10% stated interest rate, and the punitive 120% repayment clause, are significantly more expensive than typical commercial bank loans or investment-grade corporate bonds.
• Compared to venture debt or other specialized financing for early-stage biotechs, these terms are on the higher end of the cost spectrum, often seen in situations where a company has limited alternatives or is perceived as having a higher risk of default.
• While specific comparable companies are not named in the document, similar financing structures have been observed in small-cap biopharmaceutical companies that are pre-revenue or in early clinical stages, where access to capital is constrained and the cost of funding reflects the inherent risks of drug development and commercialization.

Stakeholder Impact

• Shareholders: The high cost of this debt could negatively impact future profitability and potentially necessitate further dilutive equity raises if the Company struggles with repayment. The unfavorable terms may signal underlying financial weakness.
• Creditors (Lender): Ionic Ventures, LLC benefits from a high return on investment, strong default protections, and a significant premium if the note is not repaid very quickly.

Next Steps

• Repayment of the Promissory Note by the Maturity Date of July 15, 2025, or earlier, under the specified terms.

Key Dates

Recommendation

Keywords

Promissory Note, Debt Financing, Original Issue Discount, Working Capital, SEC Filing, 8-K, Biopharma, High-Yield Debt, Corporate Finance